Bayer Australia - Canesten Clotrimazole

Therapeutic Goods Act 1989

Approval under section 42DF for use of restricted representations by Bayer Australia Ltd

I, Simon Waters, Delegate of the Secretary to the Department of Health, on receipt of an application from Bayer Australia Ltd, have approved under section 42DF of the Therapeutic Goods Act 1989 (the Act) the restricted representations described in paragraph (a) below for use in advertisements directed to consumers, for the products identified in paragraph (b):

1. Consult your healthcare professional before use if:
   • you have diabetes
   • you may have a condition that makes you susceptible to thrush, such as diabetes
2.  
   • Canesten Clotrimazole Thrush 3 Day Cream 20mg/g (AUST R 18704)
   • Canesten Clotrimazole Thrush 6 Day Cream 10mg/g (AUST R 18699)
   • Canesten Clotrimazole Thrush 1 Day Pessary 500mg & Cream 10mg/g (AUST R 92426)
   • Canesten Clotrimazole Thrush 6 Day Pessary 100mg (AUST R 92391)
   • Canesten Clotrimazole Thrush 1 Day Pessary 500mg (AUST R 92390)
   • Canesten Clotrimazole Thrush 1 Day Cream 500mg/5g (AUST R 68570)

Dated this 19th day of September 2017

Simon Waters
Delegate of the Secretary to the Department of Health
Advertising Compliance Unit
Regulatory Practice, Education and Compliance Branch